Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 11, 2025Open Access

Ixazomib Enhances the Antitumor Effect of Olaparib by Inducing Functional HRD in Ovarian Cancer Cells

View Full Paper
Ask AI
Bookmark
Share

Authors

YOYosuke OkuiTOTsuyoshi OhtaHSHirotsugu Sakaki

Discussion

Loading...

Member takes

Overview

Screening identified ixazomib as an agent that enhances olaparib sensitivity in ovarian cancer, suggesting potential to overcome treatment resistance.

Key Points

  • Ixazomib significantly reduces tumor growth when combined with olaparib in ovarian cancer cells.
  • In vitro studies revealed that ixazomib enhanced olaparib sensitivity by inducing functional HRD.
  • Mechanistic studies showed enhanced apoptosis and suppression of RAD51 foci formation with the combination treatment.
  • Combination therapy in a xenograft mouse model demonstrated significant tumor reduction without severe toxicity.

Cite This Study

Okui et al. (2025) studied this question.

synapsesocial.com/papers/68d418cd713b0b5dfea63fbehttps://doi.org/10.20944/preprints202509.0840.v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1HAMNO and CGK733 as BRCAness-driven candidates exhibit synthetic lethality with olaparib in BRCA-proficient ovarian cancer2026
  2. 2Synergistic effects of the curcumin analog HO-3867 and olaparib in transforming fallopian tube epithelial cells2025
  3. 3Ivabradine induces RAD51 degradation, potentiating PARP inhibitor efficacy in non-germline BRCA pathogenic variant triple-negative breast cancer2025
  4. 4Homologous Repair‐Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy2025
  5. 5Abstract A020: COPS5 Inhibition sensitizes high-grade serous ovarian cancer to PARP inhibition via R-loop–mediated DNA damage2025